© Copyright 2004-2016 PharmaInformatic Boomgaarden. All rights reserved.         Site map           Contact         Terms of Use         Imprint        

 
Newspapers reports
about PharmaInformatic,
click here to read.



  Get In Contact
    LinkedIn   Twitter


Direct access to all pages:



Site map


 In the News:

Artificial Intelligence optimizes discovery of future drugs

Read press release (pdf)

 

PharmaInformatic was founded in 2004 and provides ADME Knowledge Bases and predictive tools (Expert Systems) to improve drug discovery and development. The company is based in Emden, Germany. About two-thirds of drug candidates fail in clinical trials due to lack of efficacy (insufficient drug-uptake).  Pharmaceutical companies use IMPACT-F to evaluate drug-uptake in humans prior to clinical trials.

 

Our research replaces animal testing:

A large number of animal trials is carried out every day to select and optimise drug compounds. New effective drugs must be taken up into the human body ("oral bioavailability") otherwise itís a waste of time, money and resources.

Drug uptake is tested in animals such as dogs, rats, monkeys or mice to estimate uptake in humans. But human and animal drug uptake is different (see blockbuster drug examples) and this can misguide your research to ineffective drug candidates.

The expert system IMPACT-F evaluates oral drug uptake significantly more reliably than animal tests. Pharmaceutical companies use the technology to optimise the development of novel drugs (see customers testimonials).
 

 

IMPACT-F:  Prediction of oral bioavailability in humans (drug-uptake)

The expert system IMPACT-F accelerates drug discovery and development: It calculates oral bioavailability of future drugs in humans. The technology is used to optimise lead candidates. Predictions were shown to be much more precise than animal trials: they were as accurate as the common deviation between individual humans taking part in the same clinical trial. Read our current research results on bioavailability of drugs.


 

PACT-F:  Largest knowledge base on bioavailability of drugs worldwide

PharmaInformatic has developed PACT-F, which is the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals, see content of PACT-F. Since 2005 the detailed results and conditions of more than 5000 scientific publications concerning the bioavailability of drugs have been evaluated and integrated into the database (more).


Oral bioavailability is one of the most important properties of a drug. If a new drug candidate has low or no oral bioavailability, further drug development is stopped. Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Efficacy issues have been identified as the main reason why clinical trials fail.